As with most other industries, the early life science R&D drug discovery sector is facing cost-pressure and increasingly higher demands to the products in terms of cost, quality, and time-to-market. Addi-tionally, the complexity of involved targets and systems, requirements for rapid, safe, and developable candidates are increasing.
Members-Only Content
This content is restricted to members only.
You must be logged in with an active membership to access this page.
Please click the link below to log in. If you do not have an account or your membership is inactive, you may need to register or renew it.